WASHINGTON -- Darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) significantly improved outcomes compared with ADT alone in men with metastatic hormone-sensitive prostate cancer (mHSPC), ...
Safety results were reported descriptively for the NUBEQA plus ADT arm only, as safety data were not routinely collected in the CHAARTED ADT-alone arm. In the NUBEQA plus ADT matched population, 58% ...
Adding a longer course of androgen deprivation therapy to postoperative radiotherapy may prolong metastasis-free survival in patients with prostate cancer. Adding a longer course of androgen ...
Adding 6 months of androgen deprivation therapy (ADT) to dose-escalated radiation therapy (RT) does not provide a survival advantage to patients with intermediate-risk prostate cancer, but it does ...
Impact of cabazitaxel on metastatic bone health in patients with castration resistant prostate cancer previously treated with docetaxel: CaBone Study. Background: Androgen deprivation therapy (ADT) by ...
Despite stage migration, a significant number of patients with prostate cancer develop metastasis despite curative intent primary therapy or are diagnosed with de novo metastatic disease. Until ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results